Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19
Status:
Recruiting
Trial end date:
2022-01-15
Target enrollment:
Participant gender:
Summary
Interferon lambda is one of the main arms of the innate antiviral immune response and is
critical for controlling respiratory viral infections in mice. Interferon lambda has a better
side effect profile than other interferons because of the limited tissue distribution of its
receptor. Peginterferon lambda is a long-acting form that has been studied extensively in
human trials in viral hepatitis, confirming its safety. We propose to evaluate
peginterferon-lambda in ambulatory and hospitalized patients with mild to moderate COVID-19.